Cancer Drug Price Cap: Need for Comprehensive Pharmaceutical Pricing Reform

27 Oct 2026

Tags: Social Justice   Social Services   Health sector issues

Source: The Indian Express

Context: The Centre has informed the Supreme Court that trade margins on specified non-scheduled cancer medicines will be capped at 30%, raising broader questions about drug affordability, healthcare quality and the sustainability of medical supplies.

• The key challenge is to regulate excessive margins without creating medicine shortages, restricting patient access or discouraging investment in healthcare infrastructure.

Proposed Regulation of Cancer Drug Prices

• Trade-margin cap: The government proposes a 30% cap on trade margins for specified cancer medicines.
• Implementation: An expert committee will identify the medicines to be covered, following which the National Pharmaceutical Pricing Authority (NPPA) will examine its recommendations.
• Supreme Court's concern: The Court has questioned why similar scrutiny should not extend to other medicines and medical products.
• Policy objective: Ensure affordable medicines while preventing unjustified mark-ups across the pharmaceutical supply chain.

Why Is a Comprehensive Approach Necessary?

• Fragmented regulation: Regulating one category at a time may shift pricing distortions to other products, create uncertainty and complicate enforcement.
• Evidence-based intervention: Price regulation should identify where excessive margins exist and determine the appropriate intervention based on reliable cost and market data.
• Product-specific differences: Medicines, medical devices and consumables have different manufacturing, storage, distribution and handling requirements; therefore, a uniform formula may not be suitable for every product.
• Stakeholder consultation: Manufacturers, distributors, hospitals, clinicians, insurers, patient groups and State governments can provide evidence to support workable pricing policies.

Distinguishing Trade Margins from Healthcare Delivery Costs

• Trade margins: The difference between a product's purchase price and its selling price within the supply chain, subject to the applicable pricing framework.
• Clinical and infrastructure costs: The total cost of healthcare delivery may include specialist supervision, hospital infrastructure, infection control, patient monitoring, emergency support and safe administration.
• Variation across hospitals: The same medicine may involve different delivery costs depending on the patient's condition, treatment complexity and available clinical facilities.
• Policy implication: Regulation must distinguish excessive product mark-ups from legitimate costs necessary to maintain quality, safety and continuity of care.

Lessons from Earlier Government Intervention

• 2019 pilot: The government introduced a trade-margin rationalisation pilot covering 42 selected non-scheduled anti-cancer medicines.
• Implementation concerns: Subsequent consultations raised issues concerning production costs, the viability of smaller manufacturers and the sustainability of supplies to remote areas.
• Way forward: These experiences should inform future decisions on the scope of regulation, the level of permissible margins and safeguards against supply disruptions.

Potential Risks of Poorly Designed Price Controls

• Medicine shortages: If regulated prices make supply commercially unviable, manufacturers or distributors may reduce supplies or withdraw products.
• Reduced geographical access: Smaller suppliers may struggle to serve remote and low-volume markets if legitimate distribution costs are not recognised.
• Quality concerns: Inadequate financial viability could affect investment in storage, handling, infrastructure and patient-safety standards.
• Lower healthcare investment: Blanket controls that ignore differences in cost and complexity could discourage hospitals from expanding facilities, adopting advanced technologies and strengthening clinical capabilities.

Additional UPSC-Relevant Information: Drug Price Regulation in India

• National Pharmaceutical Pricing Authority (NPPA): An attached office of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, responsible for implementing and enforcing pharmaceutical price controls.
• Drug Price Control Order (DPCO), 2013: Issued under the Essential Commodities Act, 1955, it provides the framework for regulating prices of scheduled formulations and monitoring prices of non-scheduled formulations.
• Scheduled vs non-scheduled medicines: Scheduled formulations are included in the National List of Essential Medicines (NLEM) and are subject to applicable ceiling-price controls under the DPCO. Non-scheduled formulations are governed by separate provisions, including restrictions on annual price increases.
• Trade-margin rationalisation: This approach regulates the margins permitted along the supply chain rather than necessarily fixing a medicine's price through the same mechanism used for scheduled formulations.

Way Forward

• Comprehensive review: Examine trade margins across medicines, medical devices and consumables using a common, scientifically credible assessment framework.
• Differentiated regulation: Set appropriate interventions according to product characteristics, supply-chain costs, market competition and patient-safety requirements.
• Supply safeguards: Monitor availability, manufacturer participation and distribution, particularly in remote areas and for critical cancer therapies.
• Outcome-based evaluation: Assess whether patients obtain fairer prices without shortages, reduced access or compromised quality.
• Sustainable healthcare investment: Ensure that pricing policies preserve incentives for infrastructure expansion, technological adoption and quality clinical care.

Conclusion: India needs a pharmaceutical pricing framework that balances affordability, availability, quality and sustainability. The success of cancer drug price regulation should be measured not merely by the number of products covered, but by whether patients receive affordable, safe and reliable treatment without undermining the healthcare system's capacity to deliver quality care.